Rosa Lilo

Dr. Rosa Lilo

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
MMMaria Beatrice Musumeci
Maria Beatrice Musumeci
VMVittoria Mastromarino
Vittoria Mastromarino
MCMatteo Casenghi
Matteo Casenghi
GTGiacomo Tini
Giacomo Tini
PFPietro Francia
Pietro Francia
CACamillo Autore
Camillo Autore

28 July 2022 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
MMmaria chiara meucci
maria chiara meucci
RLRosa Lilo
Rosa Lilo
ALAntonella Lombardo
Antonella Lombardo
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
MBMarianne Bootsma
Marianne Bootsma
Francesca GrazianiFrancesca Graziani
Francesca Graziani
To perform a comparative analysis of right ventricle (RV) myocardial mechanics, assessed by 2D speckle-tracking echocardiography (2D-STE), between patients with Fabry disease and patients with sarcomeric disease. Patients with Fabry cardiomyopathy (FC) (n = 28) were compared with patients with sarcomeric hypertrophic cardiomyopathy (HCM), matched for degree of left ventricle hypertrophy (LVH) and demographic characteristics (n = 112). In addition, patients with Fabry disease and no LVH [phenotype-negative carriers of pathogenic α-galactosidase gene mutations (GLA LVH-)] (n = 28) were compared with age and sex-matched carriers of sarcomeric gene mutations without LVH [Phenotype-negative carriers of pathogenic sarcomeric gene mutations (Sarc LVH-)] (n = 56). Standard echocardiography and 2D-STE were performed in all participants. Despite a subtle impairment of RV global longitudinal strain (RV-GLS) was common in both groups, patients with FC showed a more prominent reduction of RV free wall longitudinal strain (RV-FWS) and lower values of difference between RV-FWS and RV-GLS (ΔRV strain), in comparison to individuals with HCM (P < 0.001 and P = 0.002, respectively). RV-FWS and ΔRV strain demonstrated an independent and additive value in discriminating FC from HCM, over the presence of symmetric LVH, systolic anterior motion of the mitral valve and RV hypertrophy. Similar results were found in GLA LVH- patients: they had worse RV-FWS and lower values of ΔRV strain as compared to Sarc LVH- patients (both P < 0.001). Patients with FC show a specific pattern of RV myocardial mechanics, characterized by a larger impairment of RV-FWS and lower ΔRV strain in comparison to patients with HCM, which may be helpful in the differential diagnosis between these two diseases.

3 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
RLRosa Lilo
Rosa Lilo
MMmaria chiara meucci
maria chiara meucci
AFAnnamaria Del Franco
Annamaria Del Franco
EMEmanuele Monda
Emanuele Monda
GIGiulia Iannaccone
Giulia Iannaccone
Francesca GrazianiFrancesca Graziani
Francesca Graziani
Background: Fabry disease can be classified in 4 stages based on the extent of cardiac damage assessed with echocardiography. This staging is strongly associated with prognosis, with a doubled risk increase of cardiovascular events for each stage progression. The aims of the present study were to investigate the evolution of cardiac damage using this staging system during midterm follow‐up and to identify predictors of stage worsening. Methods AND RESULTS: This is a retrospective, multicenter study, which included 168 patients with Fabry disease (38% men) categorized at baseline and follow‐up in 4 stages, defined as follows: stage 0, no cardiac involvement; stage 1, left ventricular hypertrophy; stage 2, left atrial enlargement; and stage 3, ventricular impairment. After a median of 5 years, cardiac stage worsened of at least 1 class in 34 patients (24% of 143 patients in stage 0–2 at baseline), improved in 9 (12% of 73 patients in stages 1–3 at baseline), and remained stable in 125 (74% of the 168 patients enrolled). At multivariable logistic regression analysis, age (odds ratio, 1.05 [95% CI, 1.01–1.09]; P =0.006), male sex (odds ratio, 4.26 [95% CI, 1.54–11.79]; P =0.005), classic phenotype (odds ratio, 4.95 [95% CI, 1.30–18.72]; P =0.018), and renal failure (odds ratio, 10.40 [95% CI, 1.57–68.77]; P =0.015) emerged as independent predictors of cardiac damage stage deterioration. Conclusions: Fabry disease is associated with a high rate of progression of cardiac damage during midterm follow‐up, with ≈24% of patients experiencing cardiac stage worsening. Age, male sex, classic phenotype, and renal failure are independent predictors of stage progression.

1 April 2026 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
EMEmanuele Monda
Emanuele Monda
ABAthanasios Bakalakos
Athanasios Bakalakos
AFAnnamaria Del Franco
Annamaria Del Franco
RLRosa Lilo
Rosa Lilo
MMmaria chiara meucci
maria chiara meucci
Perry ElliottPerry Elliott
Perry Elliott
BACKGROUND: Cardiac involvement is the main determinant of adverse outcomes in Fabry disease. The study aimed to investigate cardiovascular outcomes in patients with Fabry disease. METHODS: This was a multicenter, retrospective, longitudinal study of consecutively referred adult patients with Fabry disease. The primary end point was the occurrence of major adverse cardiovascular events defined as a composite of cardiovascular death, major arrhythmic events, bradyarrhythmias requiring pacemaker implantation, and stroke. RESULTS: A total of 680 patients (age, 42.3±15.9 years; 41.0% male; 68.7% on disease-specific therapy) were included. During a median follow-up of 7.1 (interquartile range, 3.9–11.6) years, 92 patients (13.5%) experienced a major adverse cardiovascular event. At 10 years, freedom from major adverse cardiovascular event was 85.1% (95% CI, 81.3–88.2) and was lower in men compared with women (76.1% [95% CI, 68.9–81.9] versus 91.3% [95% CI, 87.0–94.2]; log-rank χ 2 =26.9; P <0.001). On multivariable analysis, age (hazard ratio, 1.04 [95% CI, 1.01–1.06] per 1 year; P <0.001), estimated glomerular filtration rate (hazard ratio, 0.99 [95% CI, 0.98–0.99] per 1 mL/min per 1.73 m 2 ; P <0.001), QRS interval (hazard ratio, 1.02 [95% CI, 1.01–1.03] per 1 ms; P =0.002), and left ventricular mass index (hazard ratio, 1.01 [95% CI, 1.00–1.01] per 1 g/m 2 ; P =0.032) were independent predictors of major adverse cardiovascular events during follow-up. CONCLUSIONS: This study shows that the prevention and treatment of cardiovascular disease remain an unmet need for patients with Fabry disease.

22 July 2024 in Mitochondrion
Verified
Journal Article
Closed access
RLRosa Lilo
Rosa Lilo
MMMaria Chiara Meucci
Maria Chiara Meucci
SMSilvia Malara
Silvia Malara
GPGuido Primiano
Guido Primiano
SSSerenella Servidei
Serenella Servidei
Francesca GrazianiFrancesca Graziani
Francesca Graziani

25 September 2025 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
MMmaria chiara meucci
maria chiara meucci
RLRosa Lilo
Rosa Lilo
AFAnnamaria Del Franco
Annamaria Del Franco
EMEmanuele Monda
Emanuele Monda
GIGiulia Iannaccone
Giulia Iannaccone
Francesca GrazianiFrancesca Graziani
Francesca Graziani
Aims: Left ventricular hypertrophy (LVH) is one of the main prognostic factors in Fabry disease (FD). Despite the known impact of sex on the phenotypic expression of the disease, a ‘fixed’ threshold of left ventricular maximal wall thickness (LVMWT) > 12 mm is conventionally used for defining overt cardiac involvement. We aimed to investigate sex-differences in the association between LVH degree and cardiovascular outcomes in FD. Methods and results: In this multicenter retrospective study, 347 patients with FD (57% women) were enrolled and echocardiographic data collected. The study endpoint was defined as the composite of mortality, hospitalization for heart failure, atrial fibrillation, major brady- or tachy-arrhythmias and ischaemic stroke. Women had lower LV wall thickness and LV mass than men and these differences were confirmed also indexing for body surface area (BSA) (all P < 0.001). After a median follow-up of 53 (IQR: 26–90) months, 64 patients (18%) met the study endpoint. The composite-event rate at 8 years was significantly higher in men vs. women (33% vs. 11%; P = 0.015). Values of LVMWT > 10 mm (or indexed LVMWT > 6.1 mm/m2) were associated with an increased risk of the composite endpoint in women, while a LVMWT prognostic threshold of 13 mm (or 6.9 mm/m2) was identified in men (both P < 0.001). These cut-off values were independently associated with outcomes, after adjustment for age, exposure to specific therapy and renal function. Conclusion: In FD patients, sex-specific prognostic thresholds of LVH were identified, with women experiencing cardiovascular events at significantly lower values of LVMWT than men, even after accounting for BSA.